138 related articles for article (PubMed ID: 26607351)
1. Role of LCAT in Atherosclerosis.
Ossoli A; Simonelli S; Vitali C; Franceschini G; Calabresi L
J Atheroscler Thromb; 2016; 23(2):119-27. PubMed ID: 26607351
[TBL] [Abstract][Full Text] [Related]
2. Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans.
Calabresi L; Franceschini G
Trends Cardiovasc Med; 2010 Feb; 20(2):50-3. PubMed ID: 20656215
[TBL] [Abstract][Full Text] [Related]
3. The role of lecithin:cholesterol acyltransferase in the modulation of cardiometabolic risks - a clinical update and emerging insights from animal models.
Ng DS
Biochim Biophys Acta; 2012 Apr; 1821(4):654-9. PubMed ID: 22326749
[TBL] [Abstract][Full Text] [Related]
4. Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?
Kunnen S; Van Eck M
J Lipid Res; 2012 Sep; 53(9):1783-99. PubMed ID: 22566575
[TBL] [Abstract][Full Text] [Related]
5. A review on lecithin:cholesterol acyltransferase deficiency.
Saeedi R; Li M; Frohlich J
Clin Biochem; 2015 May; 48(7-8):472-5. PubMed ID: 25172171
[TBL] [Abstract][Full Text] [Related]
6. Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease.
Rousset X; Vaisman B; Amar M; Sethi AA; Remaley AT
Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):163-71. PubMed ID: 19306528
[TBL] [Abstract][Full Text] [Related]
7. Novel LCAT (Lecithin:Cholesterol Acyltransferase) Activator DS-8190a Prevents the Progression of Plaque Accumulation in Atherosclerosis Models.
Sasaki M; Delawary M; Sakurai H; Kobayashi H; Nakao N; Tsuru H; Fukushima Y; Honzumi S; Moriyama S; Wada N; Kaneko T; Yamada K; Terasaka N; Kubota K
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):360-376. PubMed ID: 33086872
[TBL] [Abstract][Full Text] [Related]
8. Very low levels of HDL cholesterol and atherosclerosis, a variable relationship--a review of LCAT deficiency.
Savel J; Lafitte M; Pucheu Y; Pradeau V; Tabarin A; Couffinhal T
Vasc Health Risk Manag; 2012; 8():357-61. PubMed ID: 22701329
[TBL] [Abstract][Full Text] [Related]
9. Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?
Rousset X; Shamburek R; Vaisman B; Amar M; Remaley AT
Curr Atheroscler Rep; 2011 Jun; 13(3):249-56. PubMed ID: 21331766
[TBL] [Abstract][Full Text] [Related]
10. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans.
Calabresi L; Baldassarre D; Castelnuovo S; Conca P; Bocchi L; Candini C; Frigerio B; Amato M; Sirtori CR; Alessandrini P; Arca M; Boscutti G; Cattin L; Gesualdo L; Sampietro T; Vaudo G; Veglia F; Calandra S; Franceschini G
Circulation; 2009 Aug; 120(7):628-35. PubMed ID: 19687369
[TBL] [Abstract][Full Text] [Related]
11. Atherosclerosis in aged mice over-expressing the reverse cholesterol transport genes.
Berti JA; de Faria EC; Oliveira HC
Braz J Med Biol Res; 2005 Mar; 38(3):391-8. PubMed ID: 15761619
[TBL] [Abstract][Full Text] [Related]
12. Loss of LCAT activity in the golden Syrian hamster elicits pro-atherogenic dyslipidemia and enhanced atherosclerosis.
Dong Z; Shi H; Zhao M; Zhang X; Huang W; Wang Y; Zheng L; Xian X; Liu G
Metabolism; 2018 Jun; 83():245-255. PubMed ID: 29526535
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency.
Simonelli S; Tinti C; Salvini L; Tinti L; Ossoli A; Vitali C; Sousa V; Orsini G; Nolli ML; Franceschini G; Calabresi L
Biologicals; 2013 Nov; 41(6):446-9. PubMed ID: 24140107
[TBL] [Abstract][Full Text] [Related]
14. Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis.
Santamarina-Fojo S; Lambert G; Hoeg JM; Brewer HB
Curr Opin Lipidol; 2000 Jun; 11(3):267-75. PubMed ID: 10882342
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous Atherosclerosis in Aged LCAT-Deficient Hamsters With Enhanced Oxidative Stress-Brief Report.
Guo M; Liu Z; Xu Y; Ma P; Huang W; Gao M; Wang Y; Liu G; Xian X
Arterioscler Thromb Vasc Biol; 2020 Dec; 40(12):2829-2836. PubMed ID: 32998519
[TBL] [Abstract][Full Text] [Related]
16. Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease.
Funke H; von Eckardstein A; Pritchard PH; Hornby AE; Wiebusch H; Motti C; Hayden MR; Dachet C; Jacotot B; Gerdes U
J Clin Invest; 1993 Feb; 91(2):677-83. PubMed ID: 8432868
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure.
Vaziri ND; Liang K; Parks JS
Kidney Int; 2001 Jun; 59(6):2192-6. PubMed ID: 11380821
[TBL] [Abstract][Full Text] [Related]
18. Compound heterozygosity (G71R/R140H) in the lecithin:cholesterol acyltransferase (LCAT) gene results in an intermediate phenotype between LCAT-deficiency and fish-eye disease.
Hörl G; Kroisel PM; Wagner E; Tiran B; Petek E; Steyrer E
Atherosclerosis; 2006 Jul; 187(1):101-9. PubMed ID: 16216249
[TBL] [Abstract][Full Text] [Related]
19. Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected].
Duivenvoorden R; Holleboom AG; van den Bogaard B; Nederveen AJ; de Groot E; Hutten BA; Schimmel AW; Hovingh GK; Kastelein JJ; Kuivenhoven JA; Stroes ES
J Am Coll Cardiol; 2011 Dec; 58(24):2481-7. PubMed ID: 22133847
[TBL] [Abstract][Full Text] [Related]
20. Controversial Role of Lecithin:Cholesterol Acyltransferase in the Development of Atherosclerosis: New Insights From an LCAT Activator.
Vitali C; Cuchel M
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):377-379. PubMed ID: 33356367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
